---
title: "CITIC International raised the target price of KELUN PHARMA to 507.11 yuan, rating it as \"Buy.\""
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280437998.md"
description: "CMB International released a research report, raising the target price for KELUN PHARMA to HKD 507.11, maintaining a \"Buy\" rating. The report pointed out that KELUN PHARMA's total revenue last year was RMB 2.06 billion, a year-on-year increase of 6.5%. Although the net loss widened to RMB 382 million due to commercialization expansion and clinical advancement, the company is well-capitalized and is expected to have RMB 4.6 billion in cash and financial assets by the end of 2025"
datetime: "2026-03-25T08:29:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280437998.md)
  - [en](https://longbridge.com/en/news/280437998.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280437998.md)
---

# CITIC International raised the target price of KELUN PHARMA to 507.11 yuan, rating it as "Buy."

Zhaoyin International published a research report stating that KELUN PHARMA (06990.HK) achieved a total revenue of RMB 2.06 billion last year, an increase of 6.5% year-on-year, with product sales revenue of RMB 543 million. The three core assets, Sac-TMT, A167, and A140, have all successfully been included in the national medical insurance catalog, laying a solid foundation for sales growth in 2026. Although the net loss expanded to RMB 382 million due to commercialization expansion and late-stage clinical advancement, the company has ample funds, with RMB 4.6 billion in cash and financial assets as of the end of 2025.

The bank raised the company's target price from HKD 498.55 to HKD 507.11, maintaining its rating as "Buy."

### Related Stocks

- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159316.CN](https://longbridge.com/en/quote/159316.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [513700.CN](https://longbridge.com/en/quote/513700.CN.md)
- [06990.HK](https://longbridge.com/en/quote/06990.HK.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [002422.CN](https://longbridge.com/en/quote/002422.CN.md)
- [159506.CN](https://longbridge.com/en/quote/159506.CN.md)
- [520880.CN](https://longbridge.com/en/quote/520880.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [159892.CN](https://longbridge.com/en/quote/159892.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [520690.CN](https://longbridge.com/en/quote/520690.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [513060.CN](https://longbridge.com/en/quote/513060.CN.md)

## Related News & Research

- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [Everest Medicines Director and Major Shareholder Raises Stake in Company](https://longbridge.com/en/news/286481551.md)
- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)
- [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md)